Sulfadicramide, a sulfonamide derivative known for its antibacterial properties, was evaluated for its pharmacokinetic characteristics through an in silico approach. The ADME profile of the compound was systematically characterized using the SwissADME web tool, which integrates multiple predictive models for drug-likeness, bioavailability, and pharmacokinetic properties. The molecule exhibited high gastrointestinal absorption and full compliance with Lipinski’s rule, indicating good potential for oral bioavailability. Blood-brain barrier permeability and P-glycoprotein substrate affinity were also assessed, suggesting limited central nervous system penetration and low susceptibility to efflux mechanisms. The compound exhibited no predicted cytochrome P450 (CYP) inhibitory activity, implying a reduced risk of metabolic drug–drug interactions. In addition, physicochemical descriptors such as logP, topological polar surface area (TPSA), and rotatable bonds were found to fall within the optimal ranges for drug-likeness. Collectively, these findings support the hypothesis that Sulfadicramide possesses a favorable pharmacokinetic profile, and highlight its potential as a lead candidate for further pharmacodynamic and in vivo evaluation.